TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02494531

Intervention type: RADIATION
Group type: OTHER
Intervention: Fluorodeoxyglucose-PET
Description: Fluorodeoxyglucose-PET performed within 2 months

Intervention type: RADIATION
Group type: OTHER
Intervention: florbetapir F 18-PET
Description: florbetapir F 18-PET performed within 2 months
Study: NCT00689572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
Study: NCT04123899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGAD→GSTD
Description: Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSTD→IGAD
Description: Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)
Study: NCT02059200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Compassionate Living
Description: The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
Study: NCT01212185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin spray
Description: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray without oxytocin
Description: 6 insufflations (0.1 metered dose/insufflation) twice daily
Study: NCT02653222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathicolysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring
Description: 1 month before and after surgery the patient will have an ABPM over 24h

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography
Description: 1 month before and after surgery the patient will have a MRA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: complete blood count, blood platelets, coagulation profile, irregular agglutinins search
Study: NCT02087904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Study: NCT00355394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Intravenous bolus administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard care including intravenous fluid, but no metoclopramide.
Study: NCT01999582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Study: NCT02237430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MynxGrip
Description: Closure device for femoral artery access closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Conventional manual compression
Study: NCT01788007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Topical Cream 3.75%
Description: Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyclara® (imiquimod) Topical Cream 3.75%
Description: Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Cream
Description: Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Study: NCT01207557

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Only
Description: 50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Plus OIDA
Description: 50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
Study: NCT04282772

Intervention type: DIAGNOSTIC_TEST
Intervention: Impacted
Description: Until an active treatment for the PFM is started or the early exfoliation of PSM occurs, the tooth remains in a self-locking position

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-corrected
Description: The ectopic erupted permanent molar can disregard the self-locking position and continue in a normal direction, but the distal root of the PSM remains more or less a significant atypical resorption
Study: NCT00632801

Intervention type: OTHER
Group type: OTHER
Intervention: chewing gum
Description: The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
Study: NCT00495651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral medications
Description: Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral medications+Isoniazid prophylaxis
Description: * Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~* Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral medications
Description: Early ART initiation on the day of inclusion, before reaching the current WHO criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral medications+Isoniazid prophylaxis
Description: * Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~* Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
Study: NCT03861637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESA for correction of PTA to 12-13g/dl
Description: To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESA for correction of PTA to 12-13g/dl
Description: To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
Study: NCT03067272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc® Permanent Contraceptive System
Description: The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
Study: NCT02690129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesteron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Progesteron
Study: NCT00774345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules given orally on days 1-28 of a 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules given orally on days 1 - 28 of a 28 day cycle
Study: NCT01899170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Implantation of a deep brain stimulation electrode into pain processing brain areas

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Implantation of a deep brain stimulation electrode into pain processing brain areas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervel Neurotech, Multi-coil TMS
Description: Non-invasive selective stimulation of deep brain areas using magnetic fields.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cervel Neurotech, Multi-coil TMS
Description: Non-invasive selective stimulation of deep brain areas using magnetic fields.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervel Neurotech, Multi-coil TMS
Description: Non-invasive selective stimulation of deep brain areas using magnetic fields.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-Carfentanil
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 11C-Carfentanil
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Carfentanil
Description: PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
Study: NCT02680379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline, then Minocycline/Lovastatin
Description: Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin, then Minocycline/Lovastatin
Description: Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
Study: NCT04395911

Intervention type: DEVICE
Group type: OTHER
Intervention: SCD
Description: cytopheretic device
Study: NCT01103674

Intervention type: DEVICE
Group type: OTHER
Intervention: Numeris®-AF Guided Coagulation System with VisiTrax®
Description: Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
Study: NCT02014064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan \& cognitive testing session)
Study: NCT04779203

Intervention type: DEVICE
Intervention: Osseodensification Densah Bur
Description: Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.

Intervention type: DEVICE
Intervention: Osseodensification Densah Bur
Description: Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.
Study: NCT01637233

Intervention type: DRUG
Intervention: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors
Description: NRTI+PI

Intervention type: DRUG
Intervention: Arm 2 Maraviroc and Protease Inhibitors
Description: maraviroc + PI

Intervention type: DRUG
Intervention: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
Description: maraviroc + NRTI
Study: NCT00278681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and ORS
Description: One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water.
Study: NCT03138876

Intervention type: DEVICE
Group type: OTHER
Intervention: EEG Cap
Description: Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-seizure medication
Description: Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard EEG
Description: An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
Study: NCT03842020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pharmacokinetic samples
Description: 1 or 3 sample(s) will be taken in the following time windows: \[H0-H3\]; \[H5-H9\] and just before the next set \[H24\], depending if the child is or is not admitted to hospital
Study: NCT01791608

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate as dietary supplementation
Description: Zinc sulfate as dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc amino acid chelate as dietary supplementation
Description: Zinc amino acid chelate as dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk without fortification without zinc
Description: Milk without fortification
Study: NCT02204696

Intervention type: PROCEDURE
Intervention: Tonsillectomy
Description: Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
Study: NCT01418976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Mobility Training (IMT)
Description: Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
Study: NCT04429061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SKILLZ-Girl curriculum
Description: Participation in the SKILLZ-Girl curriculum and SKILLZ-Club
Study: NCT01158521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
Study: NCT03934983

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT00781716

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting coronary stent system
Description: Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting coronary stent system
Description: Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
Study: NCT02087904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01979341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final oocyte maturation trigger
Description: when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final oocyte maturation trigger
Description: when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
Study: NCT02867995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drop Aid
Description: Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
Study: NCT04393922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic stimuli (Startle)
Description: A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic stimuli (Startle)
Description: A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
Study: NCT00278278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV
Study: NCT03305107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Chocolate Milk
Description: High intensity interval exercise Chocolate Milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Water
Description: High intensity interval exercise Water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting and Chocolate Milk
Description: Sitting Chocolate Milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting and Water
Description: Sitting Water
Study: NCT01727895

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan (Glucan #300®)
Study: NCT00465595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: The dose of psilocybin received in the two sessions will range anywhere from low to high.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: The dose of psilocybin received in the two sessions will range anywhere from low to high.
Study: NCT01381159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Communication
Description: Brief MC sessions focused on medication adherence within 4-6 week period

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard medical care
Study: NCT03279003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED light
Description: An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.